Popular GLP-1 weight loss drugs could soon be available for pets. Okava Pharmaceuticals, based in San Francisco, just launched MEOW-1 — a clinical study that utilizes a tiny, under-the skin implant in 50 cats to release a GLP-1 medication drug over six months.
Main Idea: Okava Pharmaceuticals has started a study of a tiny implant in cats that could deliver a GLP-1 drug for weight loss and better health.
Key Points:
Pet owners may face a new monthly cost if GLP-1 implants reach market, and the benefits and side effects are still unknown.
Okava Pharmaceuticals says the treatment could help many overweight cats avoid diabetes and live healthier lives.
Rate how each entity in this article affected the American people.
Central company launching the cat obesity drug implant study and seeking FDA approval.
Okava’s CEO, quoted making the company’s core claims about the implant and trial.
Named expert quoted on pet obesity and the potential benefits and unknowns of the treatment.
The company says it will seek approval from this regulator for cat use.
Cat owner quoted as a potential consumer of the treatment, providing a human angle.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment